Get the Stockscreener App
1.42
0.71%
0.01
After Hours:
1.41
-0.01
-0.70%
Esperion Therapeutics Inc stock is traded at $1.42, with a volume of 3.29M.
It is up +0.71% in the last 24 hours and up +44.25% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$1.41
Open:
$1.38
24h Volume:
3.29M
Relative Volume:
0.69
Market Cap:
$281.44M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-0.6698
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
-4.70%
1M Performance:
+44.25%
6M Performance:
-20.67%
1Y Performance:
-38.53%
1-Day Range:
$1.36
$1.43
1-Week Range:
$1.36
$1.74
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.42 | 279.46M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Should I hold or sell Esperion Therapeutics Inc. stock in 2025Wealth Building Review That Work - jammulinksnews.com
What are the latest earnings results for Esperion Therapeutics Inc.Free Stock Alerts For Every Investor - jammulinksnews.com
What is the risk reward ratio of investing in Esperion Therapeutics Inc. stockReal Time Watchlist With Low Risk - jammulinksnews.com
Is Esperion Therapeutics Inc. stock overvalued or undervaluedLow Risk Strategy With Low Risk - jammulinksnews.com
What institutional investors are buying Esperion Therapeutics Inc. stockReal Time Watchlist With Proven Results - jammulinksnews.com
Is Esperion Therapeutics Inc. a Top Dividend Stock to Watch in 2025Investment Strategy With Predictable Gains Outlined - metal.it
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors - MSN
What makes Esperion Therapeutics Inc. stock price move sharplyMarket Entry and Exit Point Tips From Traders - metal.it
How many analysts rate Esperion Therapeutics Inc. as a “Buy”Expert guidance for superior capital growth - jammulinksnews.com
Is Esperion Therapeutics Inc. a Top Dividend Stock to Watch in 2025 Profit Target Planning with Exit Confidence - metal.it
Why is Esperion Therapeutics Inc. stock attracting strong analyst attentionRapidly growing investment returns - jammulinksnews.com
How strong is Esperion Therapeutics Inc. company’s balance sheetUnlock powerful portfolio management tools - jammulinksnews.com
Esperion Therapeutics soars amid vague takeover speculation - MSN
Is Esperion Therapeutics Inc. a good long term investmentHigh-return market picks - PrintWeekIndia
What analysts say about Esperion Therapeutics Inc. stockFree Predictions - PrintWeekIndia
Is Esperion Therapeutics Inc. stock a good hedge against inflationFree Popular Stock Recommendations - jammulinksnews.com
Esperion Therapeutics Inc. Stock Analysis and ForecastAccelerated financial growth - PrintWeekIndia
Esperion Therapeutics soars amid vague takeover speculation (ESPR:NASDAQ) - Seeking Alpha
Esperion to Announce Second Quarter 2025 Financial Results on August 5, 2025 - Nasdaq
Esperion to Report Second Quarter 2025 Financial Results on August 5 - The Manila Times
What drives Esperion Therapeutics Inc. stock priceUnstoppable profit momentum - jammulinksnews.com
How Esperion Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - beatles.ru
Esperion settles litigation with Accord Healthcare - MSN
Esperion settles litigation with Accord Healthcare (ESPR) - Seeking Alpha
Esperion Therapeutics Settles With Accord Healthcare to Delay Nexletol Generic Version Until 2040 - MarketScreener
Esperion Therapeutics Secures Extended NEXLETOL Patent Protection: A Strategic Play for Market Dominance - AInvest
Esperion Settles Patent Litigation with Accord Healthcare to Protect NEXLETOL Until 2040 - Nasdaq
Esperion Reaches Settlement Agreement with Third ANDA Filer - GlobeNewswire
Esperion Wins Major Patent Battle: NEXLETOL Gains 15+ Years Market Exclusivity in Settlement Deal - Stock Titan
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Esperion Therapeutics, Inc. (ESPR) - ACCESS Newswire
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):